DoW Bone Marrow Failure, Investigator-Initiated Research Award
About
Summary: Supports studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in bone marrow (BMF) failure research and/or patient care. Investigator-Initiated Research Award (IIRA) applications may involve translational and clinical research including studies in preclinical models, research with human data and/or anatomical substances, and research with human subjects, as well as correlative studies associated with a clinical trial(s); however, this award mechanism does not support clinical trials. IIRA applications may also support Investigational New Drug (IND)-enabling efforts such as lead compound characterization, and assessments of formulation and stability, absorption, distribution, metabolism and excretion, dose/response and toxicology. Distinctive Features: This funding mechanism allows for a partnering Principal Investigator (PI). Only the initiating PI will submit a pre-application, but both PIs will need to submit full applications. The partnering PI application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn. This award mechanism requires preliminary data relevant to the proposed project. Applications can support clinical research studies; however, this mechanism does not allow clinical trials.
The DoW Bone Marrow Failure Investigator-Initiated Research Award supports researchers and clinicians dedicated to advancing bone marrow failure (BMF) research and improving patient outcomes. This award is designed for investigators with mature research ideas that have strong potential to make significant scientific or clinical advances in the BMF field. The program funds a wide range of research activities, including translational studies, clinical research using human data and anatomical substances, preclinical model research, and correlative studies associated with clinical trials. Notably, the award supports IND-enabling efforts such as lead compound characterization and assessments of formulation, stability, absorption, distribution, metabolism, excretion, dose-response, and toxicology. Researchers applying should have preliminary data relevant to their proposed project. A distinctive feature of this award is the option for partnering Principal Investigators to collaborate on a single research project, with both the initiating and partnering PIs required to submit full applications. While clinical research studies are eligible, the award mechanism does not support clinical trials themselves. If you are an investigator with innovative ideas to advance bone marrow failure research, this award provides an excellent opportunity to develop and expand your work with dedicated funding and institutional support.
Funding Facts
● Applications openDeadline
November 4, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Amount varies by funding cycle
Deadline
2026-11-04
Grant Type
federal
Application Cycle
Annual (Next deadline: November 4, 2026)
Best For
Research investigators with mature, innovative ideas in bone marrow failure research; translational and clinical researchers; investigators with preliminary data and institutional support
Frequently Asked Questions
Who is eligible for DoW Bone Marrow Failure, Investigator-Initiated Research Award?
Eligibility criteria are not specified in the available information. Applicants are typically research investigators with innovative ideas in bone marrow failure research. The award allows for partnering Principal Investigators on a single research project. For specific eligibility requirements regarding institution type, researcher credentials, and citizenship status, please visit the official Damon Runyon Cancer Research Foundation website.
How much funding does DoW Bone Marrow Failure, Investigator-Initiated Research Award provide?
The specific funding amount is not provided in the available information. Award amounts may vary by funding cycle. For current funding levels and budget parameters, please consult the official grant program guidelines on the Damon Runyon Cancer Research Foundation website.
How do I apply for DoW Bone Marrow Failure, Investigator-Initiated Research Award?
Applications begin with a pre-application submitted by the initiating Principal Investigator. If your project includes a partnering PI, that individual will submit a full application with an abbreviated package specific to their research portion. All associated applications may be withdrawn if either the initiating or partnering application is rejected or administratively withdrawn. Applicants must have preliminary data relevant to the proposed project. For detailed application instructions, timelines, and submission procedures, visit the Damon Runyon Cancer Research Foundation website.
What can DoW Bone Marrow Failure, Investigator-Initiated Research Award funding be used for?
This award funds translational and clinical research including preclinical model studies, research with human data and anatomical substances, and research with human subjects. It also supports correlative studies associated with clinical trials and IND-enabling efforts such as lead compound characterization, formulation and stability assessments, absorption, distribution, metabolism and excretion studies, and dose-response and toxicology evaluations. The award does not support clinical trials themselves, though clinical research studies are eligible.
Last updated: July 5, 2026